nodes	percent_of_prediction	percent_of_DWPC	metapath
Rufinamide—SCN5A—Riluzole—amyotrophic lateral sclerosis	0.724	1	CbGbCtD
Rufinamide—SCN3A—spinal nerve—amyotrophic lateral sclerosis	0.0168	0.126	CbGeAlD
Rufinamide—Iron deficiency anaemia—Riluzole—amyotrophic lateral sclerosis	0.0157	0.123	CcSEcCtD
Rufinamide—SCN11A—peripheral nervous system—amyotrophic lateral sclerosis	0.009	0.0675	CbGeAlD
Rufinamide—GRM5—hindbrain—amyotrophic lateral sclerosis	0.00708	0.0531	CbGeAlD
Rufinamide—SCN11A—nerve—amyotrophic lateral sclerosis	0.00702	0.0526	CbGeAlD
Rufinamide—SCN8A—peripheral nervous system—amyotrophic lateral sclerosis	0.00682	0.0512	CbGeAlD
Rufinamide—SCN8A—nerve—amyotrophic lateral sclerosis	0.00532	0.0399	CbGeAlD
Rufinamide—SCN10A—peripheral nervous system—amyotrophic lateral sclerosis	0.00456	0.0342	CbGeAlD
Rufinamide—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00443	0.0346	CcSEcCtD
Rufinamide—GRM5—brainstem—amyotrophic lateral sclerosis	0.00406	0.0304	CbGeAlD
Rufinamide—SCN8A—hindbrain—amyotrophic lateral sclerosis	0.00398	0.0299	CbGeAlD
Rufinamide—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00394	0.0308	CcSEcCtD
Rufinamide—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00383	0.03	CcSEcCtD
Rufinamide—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00364	0.0285	CcSEcCtD
Rufinamide—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00362	0.0284	CcSEcCtD
Rufinamide—SCN10A—nerve—amyotrophic lateral sclerosis	0.00356	0.0267	CbGeAlD
Rufinamide—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0269	CcSEcCtD
Rufinamide—CES1—Phase I biotransformations, non P450—PON1—amyotrophic lateral sclerosis	0.00305	0.207	CbGpPWpGaD
Rufinamide—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0237	CcSEcCtD
Rufinamide—SCN1A—hindbrain—amyotrophic lateral sclerosis	0.00301	0.0226	CbGeAlD
Rufinamide—SCN2A—hindbrain—amyotrophic lateral sclerosis	0.00276	0.0207	CbGeAlD
Rufinamide—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00275	0.0215	CcSEcCtD
Rufinamide—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00258	0.0202	CcSEcCtD
Rufinamide—GRM5—spinal cord—amyotrophic lateral sclerosis	0.00252	0.0189	CbGeAlD
Rufinamide—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00243	0.019	CcSEcCtD
Rufinamide—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00233	0.0183	CcSEcCtD
Rufinamide—SCN8A—brainstem—amyotrophic lateral sclerosis	0.00228	0.0171	CbGeAlD
Rufinamide—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0175	CcSEcCtD
Rufinamide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00215	0.0168	CcSEcCtD
Rufinamide—GRM5—nervous system—amyotrophic lateral sclerosis	0.00213	0.0159	CbGeAlD
Rufinamide—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0163	CcSEcCtD
Rufinamide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0163	CcSEcCtD
Rufinamide—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0161	CcSEcCtD
Rufinamide—GRM5—central nervous system—amyotrophic lateral sclerosis	0.00205	0.0154	CbGeAlD
Rufinamide—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00202	0.0158	CcSEcCtD
Rufinamide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.002	0.0157	CcSEcCtD
Rufinamide—GRM5—cerebellum—amyotrophic lateral sclerosis	0.002	0.015	CbGeAlD
Rufinamide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0156	CcSEcCtD
Rufinamide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0156	CcSEcCtD
Rufinamide—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0149	CcSEcCtD
Rufinamide—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00188	0.0147	CcSEcCtD
Rufinamide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00188	0.0147	CcSEcCtD
Rufinamide—SCN11A—spinal cord—amyotrophic lateral sclerosis	0.00187	0.0141	CbGeAlD
Rufinamide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00187	0.0146	CcSEcCtD
Rufinamide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00179	0.014	CcSEcCtD
Rufinamide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0138	CcSEcCtD
Rufinamide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00175	0.0137	CcSEcCtD
Rufinamide—SCN1A—brainstem—amyotrophic lateral sclerosis	0.00173	0.0129	CbGeAlD
Rufinamide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0131	CcSEcCtD
Rufinamide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.013	CcSEcCtD
Rufinamide—GRM5—brain—amyotrophic lateral sclerosis	0.00162	0.0122	CbGeAlD
Rufinamide—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0126	CcSEcCtD
Rufinamide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0126	CcSEcCtD
Rufinamide—SCN2A—brainstem—amyotrophic lateral sclerosis	0.00158	0.0119	CbGeAlD
Rufinamide—SCN11A—nervous system—amyotrophic lateral sclerosis	0.00158	0.0118	CbGeAlD
Rufinamide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0123	CcSEcCtD
Rufinamide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0122	CcSEcCtD
Rufinamide—GRM5—Hypothetical Network for Drug Addiction—GRIA2—amyotrophic lateral sclerosis	0.00153	0.104	CbGpPWpGaD
Rufinamide—SCN11A—central nervous system—amyotrophic lateral sclerosis	0.00152	0.0114	CbGeAlD
Rufinamide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.0015	0.0118	CcSEcCtD
Rufinamide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0114	CcSEcCtD
Rufinamide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0113	CcSEcCtD
Rufinamide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0112	CcSEcCtD
Rufinamide—SCN8A—spinal cord—amyotrophic lateral sclerosis	0.00142	0.0106	CbGeAlD
Rufinamide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0109	CcSEcCtD
Rufinamide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0109	CcSEcCtD
Rufinamide—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0105	CcSEcCtD
Rufinamide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0103	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0103	CcSEcCtD
Rufinamide—Infection—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00987	CcSEcCtD
Rufinamide—SCN9A—spinal cord—amyotrophic lateral sclerosis	0.00125	0.00936	CbGeAlD
Rufinamide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00974	CcSEcCtD
Rufinamide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00973	CcSEcCtD
Rufinamide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00965	CcSEcCtD
Rufinamide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00947	CcSEcCtD
Rufinamide—SCN11A—brain—amyotrophic lateral sclerosis	0.00121	0.00905	CbGeAlD
Rufinamide—SCN1A—medulla oblongata—amyotrophic lateral sclerosis	0.0012	0.00903	CbGeAlD
Rufinamide—SCN8A—nervous system—amyotrophic lateral sclerosis	0.0012	0.00897	CbGeAlD
Rufinamide—CES1—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.00117	0.0791	CbGpPWpGaD
Rufinamide—SCN8A—central nervous system—amyotrophic lateral sclerosis	0.00115	0.00864	CbGeAlD
Rufinamide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00899	CcSEcCtD
Rufinamide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00883	CcSEcCtD
Rufinamide—SCN8A—cerebellum—amyotrophic lateral sclerosis	0.00113	0.00844	CbGeAlD
Rufinamide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00875	CcSEcCtD
Rufinamide—SCN2A—medulla oblongata—amyotrophic lateral sclerosis	0.0011	0.00829	CbGeAlD
Rufinamide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00864	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00858	CcSEcCtD
Rufinamide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00857	CcSEcCtD
Rufinamide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00109	0.0085	CcSEcCtD
Rufinamide—SCN1A—spinal cord—amyotrophic lateral sclerosis	0.00107	0.00805	CbGeAlD
Rufinamide—SCN7A—brain—amyotrophic lateral sclerosis	0.00103	0.00769	CbGeAlD
Rufinamide—SCN2A—spinal cord—amyotrophic lateral sclerosis	0.000985	0.00739	CbGeAlD
Rufinamide—SCN3A—medulla oblongata—amyotrophic lateral sclerosis	0.000971	0.00728	CbGeAlD
Rufinamide—SCN10A—spinal cord—amyotrophic lateral sclerosis	0.00095	0.00712	CbGeAlD
Rufinamide—SCN4A—nervous system—amyotrophic lateral sclerosis	0.000938	0.00703	CbGeAlD
Rufinamide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000935	0.00732	CcSEcCtD
Rufinamide—SCN8A—brain—amyotrophic lateral sclerosis	0.000914	0.00686	CbGeAlD
Rufinamide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000911	0.00713	CcSEcCtD
Rufinamide—SCN1A—nervous system—amyotrophic lateral sclerosis	0.000904	0.00678	CbGeAlD
Rufinamide—SCN4A—central nervous system—amyotrophic lateral sclerosis	0.000903	0.00677	CbGeAlD
Rufinamide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000898	0.00703	CcSEcCtD
Rufinamide—SCN1A—central nervous system—amyotrophic lateral sclerosis	0.00087	0.00653	CbGeAlD
Rufinamide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000868	0.0068	CcSEcCtD
Rufinamide—SCN3A—spinal cord—amyotrophic lateral sclerosis	0.000865	0.00649	CbGeAlD
Rufinamide—SCN1A—cerebellum—amyotrophic lateral sclerosis	0.000851	0.00638	CbGeAlD
Rufinamide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000839	0.00657	CcSEcCtD
Rufinamide—CES1—nervous system—amyotrophic lateral sclerosis	0.000837	0.00628	CbGeAlD
Rufinamide—SCN2A—nervous system—amyotrophic lateral sclerosis	0.00083	0.00623	CbGeAlD
Rufinamide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00632	CcSEcCtD
Rufinamide—CES1—central nervous system—amyotrophic lateral sclerosis	0.000806	0.00605	CbGeAlD
Rufinamide—SCN9A—brain—amyotrophic lateral sclerosis	0.000803	0.00603	CbGeAlD
Rufinamide—Rash—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00627	CcSEcCtD
Rufinamide—SCN10A—nervous system—amyotrophic lateral sclerosis	0.0008	0.006	CbGeAlD
Rufinamide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00626	CcSEcCtD
Rufinamide—SCN2A—central nervous system—amyotrophic lateral sclerosis	0.000799	0.00599	CbGeAlD
Rufinamide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000795	0.00622	CcSEcCtD
Rufinamide—SCN2A—cerebellum—amyotrophic lateral sclerosis	0.000781	0.00586	CbGeAlD
Rufinamide—SCN10A—central nervous system—amyotrophic lateral sclerosis	0.00077	0.00578	CbGeAlD
Rufinamide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000754	0.0059	CcSEcCtD
Rufinamide—SCN3A—nervous system—amyotrophic lateral sclerosis	0.000729	0.00547	CbGeAlD
Rufinamide—SCN5A—nervous system—amyotrophic lateral sclerosis	0.000727	0.00546	CbGeAlD
Rufinamide—SCN4A—brain—amyotrophic lateral sclerosis	0.000717	0.00538	CbGeAlD
Rufinamide—SCN3A—central nervous system—amyotrophic lateral sclerosis	0.000702	0.00527	CbGeAlD
Rufinamide—SCN5A—central nervous system—amyotrophic lateral sclerosis	0.0007	0.00525	CbGeAlD
Rufinamide—SCN1A—brain—amyotrophic lateral sclerosis	0.000691	0.00518	CbGeAlD
Rufinamide—SCN3A—cerebellum—amyotrophic lateral sclerosis	0.000686	0.00515	CbGeAlD
Rufinamide—CES1—brain—amyotrophic lateral sclerosis	0.00064	0.0048	CbGeAlD
Rufinamide—SCN2A—brain—amyotrophic lateral sclerosis	0.000634	0.00476	CbGeAlD
Rufinamide—SCN10A—brain—amyotrophic lateral sclerosis	0.000612	0.00459	CbGeAlD
Rufinamide—SCN3A—brain—amyotrophic lateral sclerosis	0.000557	0.00418	CbGeAlD
Rufinamide—SCN5A—brain—amyotrophic lateral sclerosis	0.000556	0.00417	CbGeAlD
Rufinamide—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	0.000458	0.00344	CbGeAlD
Rufinamide—ALB—brain—amyotrophic lateral sclerosis	0.000445	0.00334	CbGeAlD
Rufinamide—CYP2E1—spinal cord—amyotrophic lateral sclerosis	0.000409	0.00307	CbGeAlD
Rufinamide—CYP2E1—nervous system—amyotrophic lateral sclerosis	0.000344	0.00258	CbGeAlD
Rufinamide—CYP2E1—central nervous system—amyotrophic lateral sclerosis	0.000332	0.00249	CbGeAlD
Rufinamide—CYP2E1—cerebellum—amyotrophic lateral sclerosis	0.000324	0.00243	CbGeAlD
Rufinamide—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000277	0.00208	CbGeAlD
Rufinamide—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000267	0.002	CbGeAlD
Rufinamide—CYP2E1—brain—amyotrophic lateral sclerosis	0.000263	0.00197	CbGeAlD
Rufinamide—CES1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000257	0.0174	CbGpPWpGaD
Rufinamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000243	0.0165	CbGpPWpGaD
Rufinamide—CYP2E1—Vitamin A and Carotenoid Metabolism—RARA—amyotrophic lateral sclerosis	0.000201	0.0137	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000201	0.0136	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.0002	0.0136	CbGpPWpGaD
Rufinamide—CES1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000188	0.0127	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000178	0.0121	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000163	0.0111	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000154	0.0105	CbGpPWpGaD
Rufinamide—CES1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000145	0.00982	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000143	0.00969	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000132	0.00895	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000129	0.00878	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000129	0.00878	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000129	0.00878	CbGpPWpGaD
Rufinamide—ALB—HDL-mediated lipid transport—APOE—amyotrophic lateral sclerosis	0.000129	0.00876	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000127	0.00863	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000126	0.00856	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000121	0.00822	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000121	0.00822	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000117	0.00793	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000117	0.00793	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000116	0.0079	CbGpPWpGaD
Rufinamide—CES1—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000115	0.00778	CbGpPWpGaD
Rufinamide—CES1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000113	0.00768	CbGpPWpGaD
Rufinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000113	0.00765	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—TUBA4A—amyotrophic lateral sclerosis	0.000105	0.00715	CbGpPWpGaD
Rufinamide—SCN5A—Cardiac Progenitor Differentiation—IGF1—amyotrophic lateral sclerosis	0.000103	0.00699	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.0001	0.00681	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	9.49e-05	0.00644	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	9.41e-05	0.00639	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	9.4e-05	0.00638	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	9.04e-05	0.00613	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	9e-05	0.00611	CbGpPWpGaD
Rufinamide—GRM5—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	8.72e-05	0.00591	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	8.65e-05	0.00587	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	8.65e-05	0.00587	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	8.34e-05	0.00566	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	8.34e-05	0.00566	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—PFN1—amyotrophic lateral sclerosis	8.22e-05	0.00557	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.92e-05	0.00537	CbGpPWpGaD
Rufinamide—ALB—Lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	7.42e-05	0.00503	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—C3—amyotrophic lateral sclerosis	6.73e-05	0.00457	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	6.7e-05	0.00454	CbGpPWpGaD
Rufinamide—ALB—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	6.58e-05	0.00446	CbGpPWpGaD
Rufinamide—CYP2E1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	6.31e-05	0.00428	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	6.17e-05	0.00419	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—PFN1—amyotrophic lateral sclerosis	5.86e-05	0.00398	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.8e-05	0.00394	CbGpPWpGaD
Rufinamide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—amyotrophic lateral sclerosis	5.78e-05	0.00392	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.5e-05	0.00373	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	5.35e-05	0.00363	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.33e-05	0.00361	CbGpPWpGaD
Rufinamide—ALB—Lipid and lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	4.93e-05	0.00334	CbGpPWpGaD
Rufinamide—ALB—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	4.85e-05	0.00329	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.73e-05	0.00321	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.68e-05	0.00317	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	4.67e-05	0.00317	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	4.59e-05	0.00311	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	4.37e-05	0.00296	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—MMP9—amyotrophic lateral sclerosis	4.29e-05	0.00291	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	4.25e-05	0.00288	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	4.21e-05	0.00286	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	4.18e-05	0.00283	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.91e-05	0.00265	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.85e-05	0.00261	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—MMP9—amyotrophic lateral sclerosis	3.82e-05	0.00259	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	3.82e-05	0.00259	CbGpPWpGaD
Rufinamide—ALB—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	3.82e-05	0.00259	CbGpPWpGaD
Rufinamide—GRM5—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.8e-05	0.00258	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	3.55e-05	0.00241	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—MMP9—amyotrophic lateral sclerosis	3.5e-05	0.00237	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	3.48e-05	0.00236	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.46e-05	0.00234	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.43e-05	0.00233	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	3.35e-05	0.00227	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	3.34e-05	0.00226	CbGpPWpGaD
Rufinamide—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	3.24e-05	0.0022	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.21e-05	0.00218	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.14e-05	0.00213	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.06e-05	0.00208	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.01e-05	0.00204	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	3.01e-05	0.00204	CbGpPWpGaD
Rufinamide—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	2.93e-05	0.00199	CbGpPWpGaD
Rufinamide—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	2.89e-05	0.00196	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.87e-05	0.00195	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	2.84e-05	0.00193	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.83e-05	0.00192	CbGpPWpGaD
Rufinamide—CYP2E1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.82e-05	0.00192	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	2.8e-05	0.0019	CbGpPWpGaD
Rufinamide—CYP2E1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.78e-05	0.00189	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.75e-05	0.00187	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.73e-05	0.00185	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.7e-05	0.00184	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	2.66e-05	0.00181	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.6e-05	0.00176	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.6e-05	0.00176	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.54e-05	0.00172	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.51e-05	0.0017	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.51e-05	0.0017	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.5e-05	0.00169	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.46e-05	0.00167	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.45e-05	0.00166	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.43e-05	0.00165	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	2.41e-05	0.00163	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.33e-05	0.00158	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.33e-05	0.00158	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.31e-05	0.00157	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.29e-05	0.00155	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.25e-05	0.00153	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.25e-05	0.00153	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.24e-05	0.00152	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	2.24e-05	0.00152	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	2.17e-05	0.00147	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.16e-05	0.00147	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.16e-05	0.00147	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	2.15e-05	0.00146	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.04e-05	0.00138	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	2.03e-05	0.00138	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.02e-05	0.00137	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.98e-05	0.00134	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.94e-05	0.00132	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.93e-05	0.00131	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.9e-05	0.00129	CbGpPWpGaD
Rufinamide—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	1.86e-05	0.00126	CbGpPWpGaD
Rufinamide—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	1.86e-05	0.00126	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.85e-05	0.00126	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.85e-05	0.00126	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.84e-05	0.00125	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	1.83e-05	0.00124	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	1.82e-05	0.00124	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.81e-05	0.00123	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.79e-05	0.00121	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.79e-05	0.00121	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—MMP9—amyotrophic lateral sclerosis	1.76e-05	0.0012	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	1.74e-05	0.00118	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.73e-05	0.00118	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.73e-05	0.00118	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.73e-05	0.00117	CbGpPWpGaD
Rufinamide—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	1.7e-05	0.00115	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.67e-05	0.00113	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.67e-05	0.00113	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.65e-05	0.00112	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.65e-05	0.00112	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	1.61e-05	0.00109	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.61e-05	0.00109	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.61e-05	0.00109	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.58e-05	0.00107	CbGpPWpGaD
Rufinamide—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.58e-05	0.00107	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.57e-05	0.00107	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—DAO—amyotrophic lateral sclerosis	1.56e-05	0.00106	CbGpPWpGaD
Rufinamide—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	1.49e-05	0.00101	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.47e-05	0.000997	CbGpPWpGaD
Rufinamide—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	1.34e-05	0.000912	CbGpPWpGaD
Rufinamide—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.31e-05	0.000889	CbGpPWpGaD
Rufinamide—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.29e-05	0.000877	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.26e-05	0.000853	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	1.24e-05	0.000842	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.21e-05	0.00082	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.19e-05	0.000804	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.14e-05	0.000775	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.13e-05	0.000766	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—GSR—amyotrophic lateral sclerosis	1.09e-05	0.000742	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	1.05e-05	0.000712	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.03e-05	0.000696	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	1.02e-05	0.000691	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1e-05	0.000681	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1e-05	0.000681	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	9.41e-06	0.000638	CbGpPWpGaD
Rufinamide—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	9.4e-06	0.000638	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	9.18e-06	0.000623	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.98e-06	0.00061	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.56e-06	0.000581	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.54e-06	0.000579	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	8.1e-06	0.00055	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	8.02e-06	0.000545	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.75e-06	0.000526	CbGpPWpGaD
Rufinamide—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	7.72e-06	0.000524	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	7.26e-06	0.000492	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7.05e-06	0.000478	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	6.39e-06	0.000434	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	5.5e-06	0.000373	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	5.08e-06	0.000344	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.83e-06	0.000328	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.83e-06	0.000328	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.44e-06	0.000301	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.18e-06	0.000283	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	4.17e-06	0.000283	CbGpPWpGaD
Rufinamide—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.15e-06	0.000282	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.81e-06	0.000259	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	3.65e-06	0.000248	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	3.16e-06	0.000214	CbGpPWpGaD
Rufinamide—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	3.14e-06	0.000213	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.5e-06	0.00017	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.24e-06	0.000152	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.15e-06	0.000146	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.06e-06	0.00014	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.69e-06	0.000115	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.16e-06	7.87e-05	CbGpPWpGaD
